Splash Beverage Group
Distributor of Chispo tequila and developer of a licensed cannabinoid epilepsy treatment.
Something off on this page? Send us feedback.
Profile
Distributes Chispo tequila through independent distributors while shifting from a former beverage portfolio toward a licensed cannabinoid epilepsy program. U.S. CannEpil commercialization depends on clinical trials, regulatory approval, and its Argent license.
Distributes Chispo, a blue-agave blanco tequila made in Jalisco, Mexico, through independent distributors in certain U.S. states and international markets. Sales are currently concentrated in on-premise hospitality, including Señor Frog's locations in Florida, the Bahamas, and Mexico.
Is shifting from its former multi-brand beverage portfolio toward regulated cannabinoid wellness and pharmaceutical development. Its exclusive worldwide CannEpil license covers a CBD-and-THC formulation for drug-resistant epilepsy, while its Avicanna holding is a minority investment and Medterra remains a proposed transaction.
Commercializing CannEpil in the United States requires clinical trials and a new drug application. Argent is the expected manufacturer and receives a royalty on net revenue, tying the program to clinical, regulatory, financing, and licensor-manufacturer execution.
Company facts
Key statistics
Year to date −84.1% · Average volume (30d) 4.6M
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | −$12.80 | −$0.77 | +94.0% | $3.9M | — | — | +2.93% |
| May 20, 2026Q1 FY26 | −$12.80 | −$1.88 | +85.3% | $4.2M | $4.2M | +0.5% | −4.58% |
| Feb 25, 2026Q4 FY25 | −$12.80 | −$5.88 | +54.1% | $3.6M | −$365.2K | −110.1% | +14.89% |
| Nov 19, 2025Q3 FY25 | −$11.20 | −$4.51 | +59.7% | $3.8M | — | — | −17.45% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $438.3K | $0 | $0 | −$365.2K | $4.2K | $0 | |
| Gross profit | −$30.4K | −$37.0K | −$201.3K | $47.3K | −$475.2K | −$3.6K | |
| Operating income | −$2.0M | −$1.6M | −$9.5M | −$976.4K | −$1.0M | −$2.0M | |
| Net income | −$3.7M | −$8.5M | −$9.9M | −$3.2M | −$2.1M | −$2.1M | |
| Diluted EPS | −$7.88 | −$17.88 | −$18.04 | −$5.88 | −$2.20 | −$0.67 | |
| Gross margin | -6.9% | — | — | — | -11,249.9% | — | |
| Operating margin | -463.8% | — | — | — | -23,888.4% | — |
Fiscal years (4-quarter sums)FY24 $4.2M · FY25 $73.1K
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $242.7K · Total debt $6.4M · Total assets $1.1M · Shareholders' equity −$15.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 10.96M · Float 8.58M · 78.2% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Diageo (ADR)
Premium tequila portfolio in on-premise and distributor placements.
- Jazz Pharmaceuticals
Approved cannabinoid epilepsy therapy for CannEpil's intended population.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Splash Beverage Group | $0.4715 | +10.94% | $5.2M | — | — | — | +863.8% |
| Diageo (ADR) | $92.99 | +0.05% | $51.69B | 29.5 | — | 2.6 | −2.6% |
| Jazz Pharmaceuticals | $244.54 | +0.02% | $15.36B | 16.7 | 9.7 | 3.3 | +15.6% |
| Median | 23.1 | 9.7 | 3.0 | +6.5% |